AbbVie Inc. (ABBV) News

AbbVie Inc. (ABBV): $107.91

1.02 (+0.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ABBV News Items

ABBV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABBV News Highlights

  • For ABBV, its 30 day story count is now at 151.
  • Over the past 29 days, ABBV's stories per day has been in a clear downtrend, falling by about -0.58 per 1 days.
  • The most mentioned tickers in articles about ABBV are ROKU, CMI and INFO.

Latest ABBV News From Around the Web

Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

Got $1,000? 2 Dirt-Cheap Value Stocks You Can Buy Right Now

For instance, the S&P 500's cyclically adjusted price-to-earnings ratio -- a measure of the stock market's valuation -- is currently 36.6, the highest it has been in more than 10 years. Right now, two such companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie currently trades for just 8.7 times forward earnings, while its price-to-earnings growth ratio (PEG) is 0.19.

Yahoo | April 14, 2021

Should AbbVie Be Worried About Rinvoq?

The U.S. Food and Drug Administration (FDA) has now pushed back two reviews for regulatory filings by AbbVie (NYSE: ABBV) for Rinvoq. This autoimmune disease drug is an important component of the company's growth strategy. In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried about Rinvoq.

Yahoo | April 14, 2021

3 More A+ Stocks To Buy And Hold Forever

Photo by efetova/iStock via Getty ImagesThis year started with picking three dividend-income investing stocks that scored an A+ in one or more Seeking Alpha Premium ratings. AbbVie (ABBV), AT&T (T), and Altria (MO) each had unique attributes for readers to pick. Only one of the picks performed the best so...

Chris Lau on Seeking Alpha | April 13, 2021

5 April Aces From 65 S&P 500 Dividend Aristocrats

Foreword As supplement to this article, please note that Kiplinger has published an on-line slide-show detailing the latest 2021 65 S&P Dividend Aristocrats. The article entitled 65 Best Dividend Stocks You Can Count On in 2021, is by Dan Burrows a contributing editor. While more than half this collection of...

Fredrik Arnold on Seeking Alpha | April 13, 2021

Top Research Reports for Home Depot, Toyota & IBM

Top Research Reports for Home Depot, Toyota & IBM

Yahoo | April 13, 2021

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed at $108.22 in the latest trading session, marking a -0.03% move from the prior day.

Yahoo | April 13, 2021

Taking It Easy Before Earnings

Taking It Easy Before Earnings

Yahoo | April 13, 2021

A Short Delay Is Still Bad News for AbbVie

The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. Brian Orelli: So, last week, AbbVie said that the FDA is extending its review of Rinvoq as a treatment for psoriatic arthritis.

Yahoo | April 13, 2021

2 Stocks That Are Perfect to Buy Now and Hold Until Retirement

Investors approaching retirement tend to be focused on investing prudently in those last few years before leaving the workforce, with many seeking to maximize their dividend income. AbbVie came on to the market in 2013 after being spun off from medical device company Abbott Labs. It joined a crowded landscape, competing against the likes of Johnson & Johnson, Pfizer, Merck, and Bristol Myers Squibb.

Yahoo | April 13, 2021

What Makes AbbVie (ABBV) a New Buy Stock | Investing.com

Stocks Analysis by Zacks Investment Research covering: AbbVie Inc. Read Zacks Investment Research's latest article on Investing.com

Investing.com | April 12, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7583 seconds.